ClinicalTrials.gov
public full text
Public Domain
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase II trial studies the side effects and how well imetelstat sodium works in treating younger patients with relapsed or refractory solid tumors. Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment#892385
- Chemotherapy in Treating Patients With Solid Tumors#1139347
- Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma#914589
- Icotinib Hydrochloride in Treating Patients With Advanced Cancers#1162655
- Oxaliplatin in Treating Children With Advanced Solid Tumors#1059874
Record · ID 1408328
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive